The content on this site is intended for healthcare professionals only
EBCC 2014 Satellite Symposium supported by GSK: 'Heading in the right direction? Optimal sequencing pathways for HER2-positive metastatic breast cancer'
Prof Azim talks through the latest options available for HER2-positive breast cancer.
To view the slides fullscreen click the square and arrows button at the bottom right of the player
GSK has paid for the organisational costs of the symposium, and honoraria for the chairperson and speakers. GSK has contributed to the agenda and content of this meeting.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
